Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,576 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.
Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR; BEGIN® Basal-Bolus Type 1 trial investigators. Bode BW, et al. Among authors: fisher m. Diabet Med. 2013 Nov;30(11):1293-7. doi: 10.1111/dme.12243. Epub 2013 Jun 17. Diabet Med. 2013. PMID: 23710902 Free PMC article. Clinical Trial.
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Francisco AM, Pei H, Bode B; BEGIN Basal-Bolus Type 1 Trial Investigators. Heller S, et al. Among authors: fisher m. Lancet. 2012 Apr 21;379(9825):1489-97. doi: 10.1016/S0140-6736(12)60204-9. Lancet. 2012. PMID: 22521071 Clinical Trial.
Glycemic responses to strenuous training in male professional cyclists with type 1 diabetes: a prospective observational study.
McCarthy O, Eckstein ML, Scott SN, Fontana FY, Christiansen MP, Stettler C, Fisher M, Bode B, Riddell MC, Hayes C, Lagrou PL, Southerland P, Moser O, Bracken RM. McCarthy O, et al. Among authors: fisher m. BMJ Open Diabetes Res Care. 2020 Apr;8(1):e001245. doi: 10.1136/bmjdrc-2020-001245. BMJ Open Diabetes Res Care. 2020. PMID: 32303532 Free PMC article.
Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
Roussel R, d'Emden MC, Fisher M, Ampudia-Blasco FJ, Stella P, Bizet F, Cali AMG, Wysham CH. Roussel R, et al. Among authors: fisher m. Diabetes Obes Metab. 2018 Feb;20(2):448-452. doi: 10.1111/dom.13071. Epub 2017 Sep 14. Diabetes Obes Metab. 2018. PMID: 28736942 Free PMC article. Clinical Trial.
A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen.
Bolli GB, Wysham C, Fisher M, Chevalier S, Cali AMG, Leroy B, Riddle MC. Bolli GB, et al. Among authors: fisher m. Diabetes Obes Metab. 2019 Feb;21(2):402-407. doi: 10.1111/dom.13515. Epub 2018 Oct 2. Diabetes Obes Metab. 2019. PMID: 30160030 Free PMC article.
5,576 results